

DRAFT

Shanghai Health Study

Update from the Benzene Health Research Consortium (BHRC) to
API General Committee for Special Programs

February 14, 2008

Presenter: Patsy Clegg, Chair BHRC Oversight Committee

Talking Points:

- Study protocols
 - Case accrual goals achieved by PIs based on YE07 report
 - NHL case accrual completed Jan 08 – one month extension
 - AML concluded end of June 07
- Financials
 - Sponsors have met obligations for financial support
 - API reports that progress in being made on getting appropriate documentation for Cinpathogen expenses
 - CinPathogen has requested additional funding for IT expenses in support of databases to meet QA expectations
- Contracts
 - Cinpathogen
 - Next payment contingent on final actual case accrual numbers being reported
 - Cinpathogen has 2 contract amendments that have not been executed
 - Relieve C of the need for insurance
 - Extend case accrual through Jan 08
 - Pharm-Olam - QA/QC
 - Have a contract for QA design. Expect to have 2nd contract in place by Q1.
 - Fudan University:
 - API is no longer pursuing a contract with Fudan.
 - Dr. Otto Wong, AHS, will continue to work with Dr. Fu Hua and Fudan under existing conditions or pursue a contract between AHS and Fudan.
 - University of Colorado
 - Has met contractual obligations and will be receiving scheduled final payment.
- Timeline
 - 2008:
 - Feb 2008: SRP/ERP/PI meeting

- Data Analysis
- Publications submitted
- YE08: BHRC dissolves itself

Shanghai Health Study

Update from the Benzene Health Research Consortium (BHRC) to API General Committee for Special Programs

May 21, 2008

Presenter: Patsy Clegg, Chair BHRC Oversight Committee

Talking Points:

- Study Progress
 - Case Control Study
 - Diagnoses complete
 - 700 AMLs
 - 640 NHLs
 - Exposure Assessment running about 1 month behind schedule
- Financials/Contracts
 - API reviewing documentation in preparation for making final payment of 750K to Cinpathogen
 - University of Colorado grant proposal to extend to YE08 (~300K).
- Priority: Planning for bringing the consortium to closure at the end of 2008
 - BHRC meeting scheduled for June 24 – Draft Agenda
 - Role of API post 2008
 - Role of SRP/ERP post 2008
 - Communications plan
 - Closing the financial books
- Expectation that any reports to GCSP will be done by API post 2008

DRAFT

Shanghai Health Study

Update from the Benzene Health Research Consortium (BHRC) to
API General Committee for Special Programs

November 27, 2007

Presenter: Patsy Clegg, Chair BHRC Oversight Committee

Talking Points:

- We are where we thought we would be to finish the study.
 - NHL case accrual to be completed YE07
 - AML concluded end of June 07
- Financials
 - Sponsors have met obligations for financial support
 - 08 invoices will be mailed in December 07
 - 3Q07 Financial Report approved
 - API reports that progress in being made on getting appropriate documentation for Cinpathogen expenses. There are still some unpaid invoices due to lack of proper receipts. There are still some expenses being disputed; i.e. office furniture, equipment.
 - Dr. Irons Travel & Expenses Contract – pre-Cinpathogen - has been closed. Unused disbursements have been refunded to API.
- Contracts
 - QA/QC Pharm-Olam: Expect to have contract in place by year-end.
 - Fudan University: API is no longer pursuing a contract with Fudan.
Dr. Otto Wong, AHS, will continue to work with Dr. Fu Hua and Fudan under existing conditions or pursue a contract between AHS and Fudan.
- API staff visited laboratory in Shanghai
- Timeline
 - YE07: Case Accrual completed
 - 2008:
 - Feb 2008: SRP/ERP/PI meeting
 - Data Analysis
 - Publications submitted
 - YE08: BHRC dissolves itself

Shanghai Health Study – Update to API Special Programs Committee

September 27, 2007

Presented by

Patsy Clegg, Chair Oversight Committee, Benzene Health Research Consortium

Update notes from meeting in blue font.

I began by introducing myself and thanking the committee for giving the consortium the opportunity to update them on the study. One of the members was new to the GCSP, so I gave a very brief description of the study. I noted that we had worked through some challenges this year including a budget increase and executing new contracts with the principal investigators and that we were looking forward to a successful conclusion to the study.

Talking Points:

1. All contracts, with the exception of Fudan University and the QA/QC contractor, have been executed.
 - Noted that the QA/QC contractor should be executed soon.
 - Reported that Dr. Otto Wong was getting what he needed from Fudan, so that the lack of an executed contract did not seem to be impeding the work. Also noted Dr. Fu Hua's confirmation that Fudan was providing the services and that the lack of a contract was not interfering.
2. Sufficient funds to support the revised budget have been committed by the 5 sponsors.
 - One sponsor will not be paying any of their committed funds until all contracts are executed. Sufficient monies available for short term.
 - Noted that sponsor will honor commitment to pay share.
3. To date, all milestones are being met and all payments are being made.
 - Some discussion of scope of reimbursable expenses in Cinpathogen contract.
 - a. Includes both corporate expenses and receipts
 - Some discussion of payments, but no follow-up was requested.
4. The QA/QC process is functioning. A contractor to oversee the process has been identified, but not yet contracted.
5. The time line for the study: